Updating results

1131 results

Sort: Relevance | Date

Curos for preventing infections when using needleless connectors (MTG44)

Evidence-based recommendations on Curos for preventing infections when using needleless connectors

Medical technologies guidance Published May 2019

SecurAcath for securing percutaneous catheters (MTG34)

Evidence-based recommendations on SecurAcath for securing percutaneous catheters (central venous catheters/CVCs)

Medical technologies guidance Published June 2017

The ReCell Spray‑On Skin system for treating skin loss, scarring and depigmentation after burn injury (MTG21)

Evidence-based recommendations on the ReCell Spray-On Skin system for treating skin loss, scarring and depigmentation after burn injury

Medical technologies guidance Published November 2014

PICO negative pressure wound dressings for closed surgical incisions (MTG43)

Evidence-based recommendations on PICO negative pressure wound dressings for closed surgical incisions

Medical technologies guidance Published May 2019 Last updated August 2019

Peristeen transanal irrigation system for managing bowel dysfunction (MTG36)

Evidence-based recommendations on the Peristeen transanal irrigation system for people with bowel dysfunction

Medical technologies guidance Published February 2018

Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers (MTG40)

Evidence-based recommendations on Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers

Medical technologies guidance Published January 2019

UrgoStart for treating diabetic foot ulcers and leg ulcers (MTG42)

Evidence-based recommendations on UrgoStart for treating diabetic foot ulcers and leg ulcers

Medical technologies guidance Published January 2019

The 3M Tegaderm CHG IV securement dressing for central venous and arterial catheter insertion sites (MTG25)

Evidence-based recommendations on the 3M Tegaderm CHG IV securement dressing for central venous and arterial catheter insertion sites

Medical technologies guidance Published July 2015 Last updated September 2019

E‑vita open plus for treating complex aneurysms and dissections of the thoracic aorta (MTG16)

Evidence-based recommendations on the E-vita open plus for treating complex aneurysms and dissections of the thoracic aorta

Medical technologies guidance Published December 2013 Last updated October 2018

DHT pilot: Zio Service for detecting cardiac arrhythmia

In development [GID-MT534] Expected publication date: TBC

Medical technologies guidance In development

SEM Scanner 200 for pressure ulcer prevention

In development [GID-MT533] Expected publication date: 06 July 2020

Medical technologies guidance In development

DHT pilot: Lifelight First for monitoring vital signs

In development [GID-MT532] Expected publication date: TBC

Medical technologies guidance In development

DHT pilot: MyCOPD for self-management of chronic obstructive pulmonary disease (COPD)

In development [GID-MT531] Expected publication date: TBC

Medical technologies guidance In development

DHT pilot: DECODE decision support system for the identification of dementia

In development [GID-MT536] Expected publication date: TBC

Medical technologies guidance In development

Axonics sacral neuromodulation system for bladder control in people with symptoms of overactive bladder

In development [GID-MT530] Expected publication date: 01 June 2020

Medical technologies guidance In development

PneuX for preventing ventilator-associated pneumonia in intensive care

In development [GID-MT528] Expected publication date: 11 March 2020

Medical technologies guidance In development

SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)

In development [GID-MT526] Expected publication date: TBC

Medical technologies guidance In development

Endo-Sponge for treating colorectal anastomotic leakage

In development [GID-MT539] Expected publication date: 01 September 2020

Medical technologies guidance In development

Danis Stent for acute oesophageal variceal bleeds

In development [GID-MT537] Expected publication date: 06 October 2020

Medical technologies guidance In development

Peezy Midstream for urine collection

In development [GID-MT538] Expected publication date: 03 August 2020

Medical technologies guidance In development

Episcissors-60 for guided mediolateral episiotomy

In development [GID-MT527] Expected publication date: 30 January 2020

Medical technologies guidance In development

Rezum for treating benign prostatic hyperplasia

In development [GID-MT529] Expected publication date: 06 April 2020

Medical technologies guidance In development

gammaCore for cluster headache

In development [GID-MT523] Expected publication date: 03 December 2019

Medical technologies guidance In development

Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer ID1504

In development [GID-TA10400] Expected publication date: 11 December 2019

Technology appraisal guidance In development

Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal) (TA351)

NICE is unable to make recommendations about the use of cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary…

Technology appraisal guidance Published July 2015

Naloxegol for treating opioid‑induced constipation (TA345)

Evidence-based recommendations on naloxegol (Moventig) for treating opioid-induced constipation that has had inadequate response to laxatives

Technology appraisal guidance Published July 2015

Ruxolitinib for treating polycythaemia vera (terminated appraisal) (TA356)

NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating polycythaemia vera...

Technology appraisal guidance Published September 2015

Idelalisib for treating chronic lymphocytic leukaemia (TA359)

Evidence-based recommendations on idelalisib (Zydelig) for treating chronic lymphocytic leukaemia (CLL) in adults

Technology appraisal guidance Published October 2015

Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) (TA353)

NICE is unable to make recommendations about the use of bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or…

Technology appraisal guidance Published August 2015

Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) (TA362)

NICE is unable to make a recommendation about the use in the NHS of paclitaxel as albumin-bound nanoparticles with carboplatin for untreated..

Technology appraisal guidance Published October 2015

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA327)

Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treatment and secondary prevention of deep vein thrombosis (DVT) or pulmonary embolism

Technology appraisal guidance Published December 2014

Omalizumab for previously treated chronic spontaneous urticaria (TA339)

Evidence-based recommendations on omalizumab (Xolair) for treating previously treated severe chronic spontaneous urticaria (hives)

Technology appraisal guidance Published June 2015

TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima…

Technology appraisal guidance Published February 2016

Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)

Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C

Technology appraisal guidance Published November 2015

Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)

Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (Viekirax) with or without dasabuvir (Exviera) for some types of chronic hepatitis C

Technology appraisal guidance Published November 2015

Tacrolimus and pimecrolimus for atopic eczema (TA82)

Evidence-based recommendations on non-steroidal tacrolimus and pimecrolimus for treating atopic eczema (atopic dermatitis)

Technology appraisal guidance Published August 2004

Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)

Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for the treatment of chronic hepatitis B

Technology appraisal guidance Published February 2006

Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)

Evidence-based recommendations on ramucirumab (Cyramza)

Technology appraisal guidance Published January 2016

Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)

Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer before chemotherapy is indicated

Technology appraisal guidance Published January 2016

Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)

Evidence-based recommendations on ezetimibe (Ezetrol) for treating primary heterozygous-familial and non-familial hypercholesterolaemia.

Technology appraisal guidance Published February 2016

Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (TA416)

Evidence-based recommendations on osimertinib (Tagresso) for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer

Technology appraisal guidance Published October 2016

Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61)

Evidence-based recommendations on capecitabine for treating metastatic colorectal cancer in adults

Technology appraisal guidance Published May 2003

Pre-hospital initiation of fluid replacement therapy in trauma (TA74)

Evidence-based recommendations on giving intravenous (IV) fluid replacement therapy for people with serious injuries before reaching hospital

Technology appraisal guidance Published January 2004

Fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding (TA78)

Evidence-based recommendations on fluid-filled thermal balloon and microwave endometrial ablation techniques for treating heavy menstrual bleeding (HMB)

Technology appraisal guidance Published April 2004

Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) (TA436)

NICE was unable to make a recommendation about the use in the NHS of bevacizumab for epidermal growth factor receptor mutation-positive non-small-cell lung

Technology appraisal guidance Published March 2017

Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) (TA437)

NICE is unable to make a recommendation about the use of ibrutinib with bendamustine and rituximab for relapsed or refractory chronic lymphocytic leukaemia

Technology appraisal guidance Published March 2017

Obeticholic acid for treating primary biliary cholangitis (TA443)

Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis (CBC / cirrhosis) in adults

Technology appraisal guidance Published April 2017

Guidance on the use of paclitaxel in the treatment of ovarian cancer (TA55)

Evidence-based recommendations on paclitaxel (Taxol) for treating ovarian cancer

Technology appraisal guidance Published January 2003 Last updated May 2005

Guidance on the use of electroconvulsive therapy (TA59)

Evidence-based recommendations on electroconvulsive therapy (ECT) for treating severe depressive illness, mania and catatonia

Technology appraisal guidance Published April 2003 Last updated October 2009

Elbasvir–grazoprevir for treating chronic hepatitis C (TA413)

Evidence-based recommendations on elbasvir–grazoprevir (Zepatier) for treating genotype 1 or 4 chronic hepatitis C (HCV) in adults

Technology appraisal guidance Published October 2016